| Completed | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, NCT02728050 | University of Washington | Phase 1 / Phase 2 |
| Completed | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome NCT02553941 | Brian Jonas | Phase 1 |
| Completed | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodyspl NCT02485535 | University of Chicago | Phase 1 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Completed | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leuke NCT01904136 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed o NCT02044796 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant NCT01812252 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgra NCT01624805 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacit NCT01168219 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT01132586 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia NCT00843882 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu NCT00588991 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Tre NCT00801489 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, NCT00453388 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia NCT00357565 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blast NCT00217646 | National Cancer Institute (NCI) | Phase 1 |
| Completed | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, o NCT00101179 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Tr NCT00027820 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |